anti-TROP2 CAR T-cell therapy (OBI Pharma)

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug Nameanti-TROP2 CAR T-cell therapy (OBI Pharma)

Drug Alias NameR-4702 CAR T-cells

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Trop-2ImmunostimulantsT lymphocytes stimulants

TargetsTumor-associated calcium signal transducer 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesObi Pharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesObi Pharma Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A